Monopar Therapeutics (NASDAQ: MNPR) stock soared after reporting promising preclinical results for the MNPR-101 radiopharmaceutical program.
On Thursday, Monopar Therapeutics (MNPR) revealed encouraging preclinical imaging and therapeutic effectiveness findings for its MNPR-101 radiopharmaceutical program. This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), including most triple-negative breast, colorectal, and pancreatic cancers.
The internal radiopharmaceutical development team at Monopar achieved a notable increase in tumor uptake of MNPR-101-Zr while reducing uptake in healthy tissue. A series of preclinical positron emission tomography sequential imaging studies demonstrated this achievement.
Preclinical studies reveal convincing and long-lasting anti-tumor advantages when MNPR-101 is combined with therapeutic radioisotopes.
The findings demonstrate almost total tumor elimination following just one injection of the radiopharmaceutical agent.
Earlier this week, the Human Research Ethics Committee (HREC) in Australia granted clearance to Monopar Therapeutics (MNPR), enabling the company to commence its Phase 1 dosimetry trial of MNPR-101-Zr.
The trial will include 12 subjects diagnosed with advanced cancers and employ positron emission tomography (PET) imaging to evaluate tumor uptake, distribution within normal organs, and safety.
Monopar Therapeutics (NASDAQ: MNPR) Stock Performance
MNPR stock surged 96.49% to close at $1.12 on Thursday. The traders had exchanged hands with 151,529,300 (151.52 million) shares compared to the average daily trading volume of 1.84 million.
Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.
